Posaconazole: Difference between revisions

From IDWiki
No edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
  +
== Background ==
==Therapeutic Drug Monitoring==
 
   
  +
* Azole antifungal
*Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption
 
  +
*For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy
 
  +
=== Pharmacokinetics and Pharmacodynamics ===
*For treatment, target trough >1 mg/L
 
  +
  +
* Generally distributes well, with the notable exception of non-inflamed brain
   
 
===Clinical Breakpoints===
 
===Clinical Breakpoints===
Line 10: Line 12:
 
! rowspan="2" |ECV (μg/mL)
 
! rowspan="2" |ECV (μg/mL)
 
! colspan="4" |Breakpoints (μg/mL)
 
! colspan="4" |Breakpoints (μg/mL)
! colspan="4" |Breakpoints (mm)
 
 
|-
 
|-
 
!S
 
!S
!SDD
 
 
!I
 
!I
!R
 
!S
 
 
!SDD
 
!SDD
!I
 
 
!R
 
!R
 
|-
 
|-
Line 24: Line 21:
 
|0.06
 
|0.06
 
|≤0.06
 
|≤0.06
  +
| colspan="2" rowspan="9" |
|
 
|
 
 
|≥0.12
 
|≥0.12
|
 
|
 
|
 
|
 
 
|-
 
|-
 
|[[Candida dubliniensis]]
 
|[[Candida dubliniensis]]
|
 
|
 
|
 
|
 
|
 
|
 
 
|
 
|
 
|
 
|
Line 45: Line 31:
 
|[[Candida glabrata]]
 
|[[Candida glabrata]]
 
|2
 
|2
|
 
|
 
|
 
|
 
|
 
|
 
 
|
 
|
 
|
 
|
Line 56: Line 36:
 
|[[Candida guilliermondii]]
 
|[[Candida guilliermondii]]
 
|0.5
 
|0.5
|
 
|
 
|
 
|
 
|
 
|
 
 
|
 
|
 
|
 
|
Line 67: Line 41:
 
|[[Candida kefyr]]
 
|[[Candida kefyr]]
 
|0.25
 
|0.25
|
 
|
 
|
 
|
 
|
 
|
 
 
|
 
|
 
|
 
|
Line 78: Line 46:
 
|[[Candida krusei]]
 
|[[Candida krusei]]
 
|0.5
 
|0.5
|
 
|
 
|
 
|
 
|
 
|
 
 
|
 
|
 
|
 
|
Line 89: Line 51:
 
|[[Candida lusitaniae]]
 
|[[Candida lusitaniae]]
 
|0.12
 
|0.12
|
 
|
 
|
 
|
 
|
 
|
 
 
|
 
|
 
|
 
|
Line 101: Line 57:
 
|0.25
 
|0.25
 
|≤0.06
 
|≤0.06
|
 
|
 
 
|≥0.12
 
|≥0.12
|
 
|
 
|
 
|
 
 
|-
 
|-
 
|[[Candida tropicalis]]
 
|[[Candida tropicalis]]
 
|0.12
 
|0.12
 
|≤0.06
 
|≤0.06
|
 
|
 
 
|≥0.12
 
|≥0.12
|
 
|
 
|
 
|
 
 
|-
 
|-
 
|[[Cryptococcus neoformans]]
 
|[[Cryptococcus neoformans]]
 
|
 
|
| colspan="8" rowspan="2" |
+
| colspan="4" rowspan="2" |
 
|-
 
|-
 
|[[Cryptococcus gattii]]
 
|[[Cryptococcus gattii]]
 
|
 
|
  +
|-
  +
|[[Aspergillus flavus]]
  +
|0.5
  +
|—
  +
| colspan="2" rowspan="5" |
  +
|—
  +
|-
  +
|[[Aspergillus fumigatus]]
  +
|0.25
  +
|≤0.125
  +
|>0.25
  +
|-
  +
|[[Aspergillus nidulans]]
  +
|0.5
  +
|—
  +
|—
  +
|-
  +
|[[Aspergillus niger]]
  +
|0.5
  +
|—
  +
|—
  +
|-
  +
|[[Aspergillus terreus]]
  +
|0.25
  +
|≤0.125
  +
|>0.25
 
|}
 
|}
  +
  +
== Dosing ==
  +
  +
=== Therapeutic Drug Monitoring ===
  +
*Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption
  +
*For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy
  +
*For treatment, target trough >1 mg/L
  +
*In Ontario, it may be available through [https://www.chusj.org/labotest/accueil CHU Saine-Justine] in Quebec ([https://chusj.omni-assistant.net/labo/AnalysisRegistry/AnalysisView.aspx?PK_Analysis=446 link to LTIG entry])
   
 
== Safety ==
 
== Safety ==

Latest revision as of 11:00, 22 October 2024

Background

  • Azole antifungal

Pharmacokinetics and Pharmacodynamics

  • Generally distributes well, with the notable exception of non-inflamed brain

Clinical Breakpoints

Species ECV (μg/mL) Breakpoints (μg/mL)
S I SDD R
Candida albicans 0.06 ≤0.06 ≥0.12
Candida dubliniensis
Candida glabrata 2
Candida guilliermondii 0.5
Candida kefyr 0.25
Candida krusei 0.5
Candida lusitaniae 0.12
Candida parapsilosis 0.25 ≤0.06 ≥0.12
Candida tropicalis 0.12 ≤0.06 ≥0.12
Cryptococcus neoformans
Cryptococcus gattii
Aspergillus flavus 0.5
Aspergillus fumigatus 0.25 ≤0.125 >0.25
Aspergillus nidulans 0.5
Aspergillus niger 0.5
Aspergillus terreus 0.25 ≤0.125 >0.25

Dosing

Therapeutic Drug Monitoring

  • Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption
  • For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy
  • For treatment, target trough >1 mg/L
  • In Ontario, it may be available through CHU Saine-Justine in Quebec (link to LTIG entry)

Safety

Adverse Events

  • Liver toxicity
    • Generally transient and asymptomatic and self-limited
    • See also LiverTox